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Background: Mechanisms underlying the pathology of diabetic retinopathy are still not completely understood.
Increased understanding of potential cellular pathways responsive to hyperglycemia is essential to develop novel
therapeutic strategies for diabetic retinopathy. Emerging evidence shows the impact of microRNA (miR) as a
potential novel therapeutic target. The purpose of our study was to test the hypothesis that miR-15b and miR-16
are altered by hyperglycemia in retinal endothelial cells (REC), and that miR-15b/16 play key roles in regulating
insulin signaling through a reduction in TNFα- and suppressor of cytokine signaling 3 (SOCS3)-mediated insulin
resistance pathways.
Methods: Human REC were maintained in normal (5 mM) glucose or transferred to high-glucose medium (25 mM)
for 3 days. REC were transfected with miRNA mimics (hsa-miR-15b-5p and hsa-miR-16-5p) 48 h before cell harvest.
A final concentration of 30 nM was used when transfected separately (miR-15b and miR-16) and 15 nM was used in
combination (miR-15b +miR-16). A negative control group was treated with an equal concentration of a mimic
negative control. The levels of miRNA overexpression were verified using quantitative reverse transcription-polymerase
chain reaction and real-time PCR. Western blot analyses were performed to study the levels of phosphorylated Akt
(Serine 473), Akt, SOCS3, insulin receptor, phosphorylated insulin receptor (tyrosine 1150/1151), and insulin receptor
phosphorylated on Tyr960. In addition, ELISA was used to examine cleaved caspase 3 and TNFα. Analyses were done
using unpaired Student t test. Data are presented as mean ± S.E.M.
Results: We demonstrated that the expression of miR-15b and miR-16 was reduced in human REC cultured in
hyperglycemia. Overexpression of miR-15b and/or miR-16 reduced TNFα and SOCS3 levels, while increasing
insulin-like growth factor binding protein-3 (IGFBP-3) levels and the phosphorylation of insulin receptor (IR)Tyr1150/1151 in
REC cultured in hyperglycemia. These, in turn, led to an increase of Akt phosphorylation and decreased cleavage of
caspase 3.
Conclusions: miR-15b and miR-16 play a role in the inhibition of insulin resistance via reduced TNFα and SOCS3
signaling and increased IGFBP-3 levels, resulting in REC protection from hyperglycemia-induced apoptosis. This outcome
suggests that both miR-15b and miR-16 are potential therapeutic targets for therapeutics for the diabetic retina.
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Diabetic retinopathy is the leading cause of blindness in
adults in the US [1]. Retinopathy results in vision loss
for >10,000 people with diabetes every year and is the
most common diabetic complication of the microvascu-
lature [2]. It has been reported that almost all patients
with type 1 diabetes mellitus (T1DM) and more than
60% of people with T2DM have retinopathy after 20 years
of diabetes [3]. Although much work has been com-
pleted on potential causes for diabetes-induced retinal
damage, the mechanisms of diabetic retinopathy are still
not completely understood.
It has been known that hyperglycemia is a key risk
factor that contributes to the onset and progression of
diabetic retinopathy [4-6]. Chronic hyperglycemia can
damage a variety of cell types and result in dysfunction
and failure of many organs, including the eyes [7]. In-
creased understanding of the pathological pathways as-
sociated with high glucose is critical, as few therapeutics
exist for diabetic retinopathy until late in the disease
progression where laser photocoagulation can be used in
some patients. Increased understanding of potential
cellular pathways responsive to hyperglycemia is essen-
tial to develop novel therapeutic strategies for diabetic
retinopathy.
One potential mechanism is changes in key micro-
RNAs (miR) in response to exposure to hyperglycemia.
As an emerging key regulator of gene expression, miR-
NAs have been identified and investigated for approxi-
mately 10 years. The great potency of miRNA (small
noncoding RNA molecules of 21 to 23 nucleotides) in
regulating a variety of cellular activities, including cellu-
lar development, proliferation, differentiation, and death,
has been demonstrated [8] as well as the use of miRNA
as a potential biomarker for diagnosing diseases [9-11].
miRNA expression and their functions are tissue- and
cell-type-specific. Diabetes mellitus is associated with
the altered expression of several miRNAs in insulin-
target tissues, as well as in insulin-secreting cells [12]. A
group of miRNAs, including miR-15b, miR-16, miR-21,
miR-93, miR-132, miR-146, and miR-200, have been
identified as having altered expression in diabetic retin-
opathy [13-15]. To date, however, there is only a small
number of studies completed to establish the down-
stream cellular signaling of miRNA to understand how
specific miRNA may affect the pathological mechanisms
common in diabetic retinopathy. Recently, the potential
of miR-15b and miR-16 have been investigated in dia-
betic retinopathy. The expression of miR-15b and miR-
16 was identified in human umbilical vein endothelial
cells (HUVEC), with overexpression of miR-15b or miR-
16 playing a role in the inhibition of angiogenesis
[16,17]. Another work has reported increased miR-15b
and miR-16 expression in rat retinal endothelial cells(REC) of streptozotocin (STZ)-induced diabetic rats
[14]. However, little is known about the expression of
miR-15b and miR-16 in human REC and its potential
role in the downstream cellular signaling associated with
the pathogenesis of diabetic retinopathy.
In order to best understand a potential role for key
miRNAs in diabetic retinopathy, it is first important to
establish whether specific miRNAs change in cell types
critical to retinopathy. REC, as one of the crucial cell
types substantially affected in diabetic retinopathy, have
been intensively studied in our lab, as well as others, and
the role and molecular mechanisms underlying diabetic
retinopathy have been deeply investigated [18-25]. We
previously reported that TNFα levels are increased in
REC under high-glucose conditions. TNFα increased
suppressor of cytokine signaling 3 (SOCS3) signaling, as
well as insulin receptor substrate 1 (IRS-1)Ser307 and in-
sulin receptor (IR)Tyr960 phosphorylation, leading to in-
hibition of normal insulin signaling under high-glucose
conditions [22]. miR-15b and miR-16 are predicted to
target a number of molecules, including downstream
protein involved in insulin signaling (targetscan.org). In
the present study, we tested the hypothesis that miR-15b
and miR-16 levels are altered by exposure to hypergly-
cemia in REC, and that miR-15b/16 play key roles in regu-
lating insulin signaling through a reduction in TNFα- and
SOCS3-mediated insulin resistance pathways.
Materials and methods
Cell culture
Human REC were acquired from Cell Systems Corpor-
ation (CSC, Kirkland, WA). Cells were grown in M131
medium containing microvascular growth supplement
(Invitrogen), 10 μg/ml gentamycin, and 0.25 μg/ml
amphotericin B. For experiments, the cells were main-
tained in normal (5 mM) glucose or transferred to a
high-glucose medium (25 mM) (Cell Systems) for 3 days.
Only primary cells within passage 5 were used. Cells
were quiesced by incubating in high- or normal-glucose
medium without growth supplementation for 20 h and
used to perform the experiments.
Cell transfection with microRNA mimics
REC were transfected with miRNA mimics (hsa-miR-
15b-5p and hsa-miR-16-5p) (Invitrogen, Carlsbad, CA)
using Oligofectamine (Invitrogen) following manufac-
turer instructions. miR transfection was performed 48 h
before cell harvest. A final concentration of 30 nM was
used when transfected separately (miR-15b and miR-16)
and 15 nM was used in combination (miR-15b +miR-16).
The negative control group was treated with an equal
concentration (30 nM) of a Mimic Negative Control
(Invitrogen). Other control groups, normal glucose
(NG) and high glucose (HG), were treated with 0 nM
Ye and Steinle Journal of Neuroinflammation  (2015) 12:44 Page 3 of 8mimic with Oligofectamine. The levels of miRNA over-
expression were verified using quantitative reverse
transcription-polymerase chain reaction and real-time
PCR.
Real-time quantitative PCR
The total RNA was isolated and purified using the TRI-
zol method, and the purity and quantity of RNA were
measured using Nanodrop (ND-1000). For polyA tailing
reverse-transcriptase PCR, 5 μg of total RNA was treated
with DNase I for 15 min at room temperature (Promega)
and then polyA using (polyA) polymerase (NEB; Ipswich,
MA) was added at 37°C for 1 h. The final reaction
mixtures were extracted with phenol/chloroform, pre-
cipitated with isopropanol, and re-dissolved in 25 μl
diethylpyrocarbonate (DEPC)-treated water. PolyA-tailed
RNA (6 μl) was reverse-transcribed into first-strand cDNA
using Superscript II reverse transcriptase (Invitrogen) with
the oligo-dT adapter primer 5′GCGAGCACAGAATTA
ATACGACTCACTATAGGTTTTTTTTTTTTVN3′. For
PCR, 1 μl of RT product was diluted three times and used
as a template in each reaction. The reverse primer was
from the adapter sequence 5′GCGAGCACAGAATTAAT
ACGACTCAC3′, and the forward primers were specific
to miR-15b and miR-16 mature sequences. U6 small non-
coding RNA sequence was amplified as the internal con-
trol using the primers 5′GCTTGCTTCGGCAGCACAT
ATAC (forward) and 5′TGCATGTCATCCTTGCTCAG
GG3′ (reverse). The SYBR-Green-based real-time PCR
was performed using the LightCycler 480 real-time PCR
system (Roche Applied Science; Indianapolis, IN). The
relative expression of miRNA was calculated based on the
formula 2(−Delta Delta Ct). Delta-Delta Ct values are Delta
Ctexp. − Delta Ctcont..
Western blot analysis
After rinsing with cold PBS, REC were collected in a
lysis buffer containing protease and phosphatase inhibi-
tors and scraped into tubes. Equal amounts of protein
were separated on precast tris-glycine gels (Invitrogen,
Carlsbad, CA), and then blotted onto a nitrocellulose
membrane. After blocking in TBST (10 mM Tris-HCl
buffer, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and 5%
(w/v) BSA, the membrane was treated with the appropri-
ate primary antibodies followed by incubation with sec-
ondary antibodies labeled with horseradish peroxidase.
Antigen-antibody complexes were detected by chemilu-
minescence reagent kit (Thermo Scientific, Pittsburgh,
PA). Primary antibodies used were phosphorylated Akt
(Serine 473), Akt, SOCS3, insulin receptor (all purchased
from Cell Signaling, Danvers, MA), phosphorylated insulin
receptor (tyrosine 1150/1151) (Enzo Life Sciences), insulin
receptor phosphorylated on Tyr960 (Cell Applications, San
Diego, CA), and beta actin (Santa Cruz, Santa Cruz, CA).ELISA analysis
A cleaved caspase 3 ELISA (Cell Signaling, Danvers, MA)
was used to measure levels of the active apoptotic marker
in whole retinal lysates. TNFα protein concentrations
were measured using a TNFα ELISA (ThermoFisher,
Pittsburgh, PA). For cleaved caspase 3 ELISA analyses,
equal protein was loaded (60 μg) into all wells to allow
for comparisons based on optical density (O.D.) For
the TNFα ELISA, 100 μg protein was loaded into all
wells, with analyses based on a standard curve. For
phospho-IRS1 ELISA (Cell Signaling, Danvers, MA)
analyses, 100 μg protein was loaded into all wells to
allow for comparisons based on O.D.
Statistics
Statistical analyses were done using Prism software
(GraphPad, La Jolla, CA). Analyses were done using un-
paired Student t test. Data are presented as mean ± S.E.
M. For Western blots, a representative blot is presented.
Results
The levels of miR-15b and miR-16 expression are reduced
in REC cultured in high-glucose conditions
We examined changes in miR-15b and miR-16 expression
in REC after exposure to hyperglycemia. We cultured
REC in a high-glucose medium (25 mM) and isolated the
total RNA from the cells, followed by quantitative real-
time PCR. We found that high glucose reduced the levels
of miR-15b and miR-16, as compared to a normal glucose
group (Figure 1A). Significantly decreased levels of miR-
15b and miR-16, 0.6- and 0.2-fold change, respectively,
were confirmed by quantitative real-time PCR.
Since hyperglycemia resulted in decreased expression
of miR-15b and miR-16, we wanted to increase the
miRNA expression through transfection with miRNA
mimics. REC were transfected with mimics, miR-15b,
miR-16, or miR15b + 16, at a final concentration of 30
nM for 48 h. Significant increases of the miRNA expres-
sion were confirmed by quantitative real-time PCR
(Table 1 and Figure 1B, C). mRNA expression of miR-15b
was increased by 167- and 364-fold, after transfecting with
miR-15b and miR-15b + 16 mimics, respectively. The
miR-16 expression was increased by 54- and 27-fold,
following transfection with miR-16 and miR-15b + 16
mimics.
miR-15b/16 reduced TNFα levels in hyperglycemia
Our goal was to determine whether miRNA-15b and
miRNA-16 are involved in insulin signaling. Thus, we
studied the effects of an altered miRNA expression on
potential downstream signaling pathways known to be
involved in diabetic retinopathy. We have previously
shown that TNFα levels are increased in hyperglycemia
[22]. We found that REC transfected with miR-15b/16
Figure 1 Decrease of miR-15b and miR-16 expression in hyperglycemia and transfection-induced fold changes. (A) Fold changes of
microRNA (miR)-15b and miR-16 expression are shown. After 3 days of retinal endothelial cell (REC) culture in a high-glucose (25 mM) medium,
the expression of both miR-15b and miR-16 was reduced (0.6- and 0.2-fold change, respectively) compared to that of the normal-glucose (NG;
5 mM) group. (B, C) Transfection-induced fold changes of miR-15b and miR-16 expression in REC. REC were transfected with mimics (30 nM of
final concentration) of miR-15b and/or miR-16 to increase the level of expression in a hyperglycemic condition. Approximately 167- and 54-fold
increases (miR-15b and miR-16, respectively) were detected following transfection with the mimic, compared to the high glucose (HG) control.
The y-axis is a logarithmic scale. *P < 0.05 versus HG, N = 3; data are mean ± S.E.M.
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to a control HG condition (Figure 2A). We, therefore,
demonstrated that the hyperglycemia-induced increase
of TNFα levels were decreased in REC when miR-15b/16
are overexpressed. Additionally, we have previously re-
ported that knockdown of TNFα led to a reduced phos-
phorylation of IRS-1 (Ser307), promoting normal insulin
signal transduction [22]. In the present study, increased
levels of IRS-1Ser307 phosphorylation under hyperglycemic
conditions were not changed in REC with miR overex-
pression (Figure 2B). This suggests that miR-15b and
miR-16 may work in REC activating other downstream
signaling via TNFα. It is also possible that other potential
microRNAs, which target IRS-1Ser307, counteract to main-
tain the phosphorylation of IRS-1Ser307 in hyperglycemia.
miR-15b and miR-16 reduced SOCS3 levels in
hyperglycemia
Our previous work also demonstrated that TNFα in-
creases SOCS3 signaling in REC [22]. Thus, we exam-
ined whether miR-15b and miR-16 alter SOCS3 levels in
hyperglycemia. The Western blot data showed that high
glucose significantly increased SOCS3 levels, as we ex-
pected. Overexpression of miR-15b and miR-15b/16 sig-
nificantly reduced the levels of SOCS3 in hyperglycemia
(Figure 3A). We, therefore, demonstrated that miR-15b
and miR-15b/16 play a role in suppressing SOCS3 signal-
ing in REC in hyperglycemia. Overexpression of miR-16Table 1 Fold changes of miR-15b and miR-16 expression
after transfection with miR-mimics
Experimental groups
miRNA HG miR-15b miR-16 miR-15b/16 Negative control
miR-15b 1.00 166.80 0.96 363.56 0.63
miR-16 1.00 0.24 0.24 27.33 0.75
HG high glucose, miR microRNA.alone slightly reduced SOCS3 levels, although the change
was not significantly different. Our previous study also
showed that knockdown of SOCS3 decreased phosphoryl-
ation of IRTyr960, which inhibited REC apoptosis through
maintenance of normal insulin signaling [22]. In the
present study, we found that the levels of IRTyr960 in
hyperglycemia were not affected by miR-15b and miR-16
overexpression (Figure 3B). This may indicate that miR-
15b and miR-16 play a role in activating other down-
stream pathways via SOCS3.
miR-15b and miR-16 increase the phosphorylation of
IRTyr1150/1151
We previously reported that the increase of SOCS3 and
TNFα, in hyperglycemia, is associated with increased
levels of IRS-1Ser307 phosphorylation and decreased
phosphorylation of IRTyr1150/1151, leading to inhibition of
normal insulin signaling [22,26]. In this study, we
showed that miR-15b and miR-16 increased the levels of
IRTyr1150/1151 phosphorylation in REC cultured under
hyperglycemic conditions (Figure 4A). The results indi-
cate that the insulin receptor is one of the target path-
ways affected by miR-15b and miR-16 in REC, and
elevated levels of the microRNAs protect REC in
hyperglycemia.
In addition to increasing IRTyr1150/1151, we recently
demonstrated that insulin-like growth factor binding
protein-3 (IGFBP-3) NB (a non-IGF-1 binding form of
IGFBP-3) in diabetic rat retina reduced TNFα and
SOCS3 levels and restored insulin receptor phosphoryl-
ation [27]. It has been demonstrated that IGFBP-3 has
vascular protective effects [28,29], and IGFBP-3 has
IGF1-independent effects, leading to the enhancement
of cell survival [29-31]. In this study, we found that miR-
15b in REC significantly increased the levels of IGFBP-3
in hyperglycemia (Figure 4B). That suggests that miR-
15b may directly or indirectly target IGFBP-3, which
Figure 2 Changes of TNFα and IRS1 (Ser307) levels in REC. (A) Enzyme-linked immunosorbent assay (ELISA) data for tumor necrosis factor
alpha (TNFα) on retinal endothelial cells (REC) in normal glucose (NG, 5 mM) or high glucose (HG, 25 mM) and transfected groups. microRNA
(miR)-15b/16 decreased TNFα levels significantly compared to the control HG condition. (B) Western blot results for phosphorylated IRS1 on
Ser307 and total IRS1. Increased levels of insulin receptor substrate 1 (IRS-1)Ser307 phosphorylation under hyperglycemic conditions were not
changed in REC with miR overexpression. A representative blot is shown. #P < 0.05 versus NG, *P < 0.05 versus HG, N = 3; data are mean ± S.E.M.
Ye and Steinle Journal of Neuroinflammation  (2015) 12:44 Page 5 of 8contributed to the reduced signaling of TNFα and
SOCS3, as well as increased IRTyr1150/1151 phosphoryl-
ation to protect REC in hyperglycemia.
miR-15b and miR-16 increase Akt phosphorylation and
decrease apoptosis in hyperglycemia
It has been reported that reduced levels of TNFα can
result in increased Akt phosphorylation, leading to a
decrease of apoptosis [32,33]. Increased levels of cleaved
caspase 3, resulting from the increased TNFα levels,
cause cell apoptosis [34]. In hyperglycemic conditions,
reduced levels of Akt phosphorylation in REC significantly
increases pro-apoptotic proteins, including cleaved cas-
pase 3 [22]. Therefore, we studied whether the increased
expression of miR-15b and miR-16 could increase the
phosphorylation of Akt in REC. We demonstrated that
hyperglycemia reduced Akt phosphorylation, which was
increased when miR-15b and miR-16 mimics were used toFigure 3 The levels of SOCS3 and IR (Tyr960) phosphorylation in REC
(A), and insulin receptor (IR) (Tyr960) and total IR (B) on REC in normal glu
(A) The levels of SOCS3 were significantly reduced with overexpression of m
phosphorylation in HG were not affected by miR-15b and miR-16 overexpr
versus HG, N = 4; data are mean ± S.E.M.activate these specific miRNA (Figure 5A). No synergistic
or additive effects were shown in the group with miR-
combination, miR-15b/16, on Akt phosphorylation.
We also examined whether increased levels of miR-
15b and miR-16 could decrease the cleavage caspase 3
of REC in a hyperglycemic condition. ELISA results
showed that overexpression of miR-16 and miR-15b/16
significantly reduced the level of cleaved caspase 3 in
hyperglycemia (Figure 5B). These results suggest that
miR-15b and miR-16 can protect REC from apoptosis in
hyperglycemia by activating the Akt survival pathway
leading to reduced cleaved caspase 3.
Discussion
Microvascular modifications are one of the significant al-
terations in diabetic retinopathy. Our previous studies
and work of many others [35-37] have demonstrated
that REC are one of the crucial cell types that are. Western blot results for suppressor of cytokine signaling 3 (SOCS3)
cose (NG, 5 mM) or high glucose (HG, 25 mM) and transfected groups.
iR-15b and miR-15b/16 in hyperglycemia. (B) The levels of IRTyr960
ession. A representative blot is shown. #P < 0.05 versus NG, *P < 0.05
Figure 4 Changes of insulin receptor (Tyr1150/1151) phosphorylation and IGFBP-3 levels. Western blot results for phosphorylated insulin
receptor (IR) (Tyr1150/1151) to total IR (A) and insulin-like growth factor binding protein-3 (IGFBP-3) (B) on retinal endothelial cells (REC) cultured
in normal glucose (NG, 5 mM) or high glucose (HG, 25 mM) and transfected groups. (A) The levels of IRTyr1150/1151 phosphorylation were increased
by the overexpression of miR-15b and miR-16 in REC under hyperglycemic conditions. (B) miR-15b significantly increased the levels of IGFBP-3 in
REC in hyperglycemia. A representative blot is shown. #P < 0.05 versus NG, *P < 0.05 versus HG, ##P < 0.01 versus NG, **P < 0.01 versus HG, N = 6 ~ 7;
data are mean ± S.E.M.
Ye and Steinle Journal of Neuroinflammation  (2015) 12:44 Page 6 of 8substantially affected in diabetic retinopathy, yet the cel-
lular mechanisms underlying diabetic retinopathy are
unclear. A new potential factor in diabetic retinopathy is
regulation by miRNA. Our preliminary data and litera-
ture indicated potential roles of miR-15b and miR-16 in
diabetic retinopathy [14,16,17]. Thus, in this work, we
aimed to investigate changes in miR-15b and miR-16 in
association with hyperglycemia-induced damage to cul-
tured human REC. It has been reported that miR-15b/16
is expressed in multiple mammalian tissues, including
the brain, heart, skeletal muscle, liver, lung, kidney, pla-
centa, and spleen [38]. In the present study, we demon-
strate the expression of miR-15b/16 in REC and show
changes of the miRNA levels in response to hypergly-
cemia in human REC. Our results demonstrated that the
expression levels of miR-15b and miR-16 were reducedFigure 5 Effects of miR-15b and miR-16 on Akt phosphorylation and
glucose (NG, 5 mM) or high glucose (HG, 25 mM). (A) Western blot results
Overexpression of microRNA (miR)-15b and miR-16 increased the levels of
A representative blot is shown. (B) Enzyme-linked immunosorbent assay (E
reduced the level of cleaved caspase 3 in hyperglycemia. #P < 0.05 versus Nin hyperglycemia. There is still only limited information
on the effects of hyperglycemia with regard to miR-15/
16. A study reported that high glucose did not cause
changes of the level of miR-16 in mouse embryos
in vitro [39]. However, others have shown that miR-15b
was increased in the REC in STZ-induced diabetic rats,
[14]. In addition to miR-15b and miR-16, other work has
shown that miR-200b was downregulated in a high-
glucose condition and played a role on glucose-induced
VEGF upregulation in HUVEC [40]. Additionally, high
glucose decreased the expression of miR-146a in HUVEC,
which can function in regulating extracellular matrix pro-
tein production in diabetes [41].
Our previous work has shown that high glucose
increases TNFα and SOCS3 protein levels in REC. In
addition, increased levels of TNFα and SOCS3 lead tocleaved caspase 3 in hyperglycemia. REC were cultured in normal
for phosphorylated Akt to total Akt on retinal endothelial cells (REC).
Akt phosphorylation, which was reduced in the control HG condition.
LISA) results for cleaved caspase 3. miR-16 and miR-15b/16 significantly
G, *P < 0.05 versus HG, N = 4; data are mean ± S.E.M.
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IR (Tyr960), and decreased phosphorylation of IR
(Tyr1150/1151), leading to insulin resistance and in-
creased apoptosis [22,26]. In the present study, we dem-
onstrated that an increased level of miR-15b and/or
miR-16 in REC resulted in decreased signaling of TNFα
and SOCS3, indicating the role of the microRNAs as
regulators of these cytokine pathways in response to
hyperglycemia. For the levels of IR (Tyr960) and
IRS-1Ser307 phosphorylation in hyperglycemia, we did
not find changes in these phosphorylated proteins
after overexpression of mIR-15b/16. The results may
indicate that miR-15b and miR-16 work in REC by
activating other downstream molecules through TNFα
and SOCS3 signaling, rather than targeting IRS-1 or
IRTyr960. Regulatory networks between miR and their tar-
gets are complex, since a single miRNA can bind to hun-
dreds of target genes, and a target gene can be regulated
by multiple miRNAs [42,43]. Each molecule at different
levels of insulin signaling is targeted by a variety of miR-
NAs. Different miRNAs are involved in the expression of
signaling proteins, such as insulin, insulin receptor, IRS-1
and IRS-2, and Akt [44]. It is possible that other potential
groups of microRNAs, which target IR (Tyr960) and
IRS-1Ser307, counteracted the effects of miR-15b and
miR-16 on the inhibition of insulin signaling in REC
cultured in hyperglycemia. It is reported that the num-
ber and abundance of miR targets decreases the ability
of a single miR to suppress their targets [45]. Another
possibility is that TNFα- and SOCS3-responsive miR
(currently unknown) were activated in the signal trans-
duction and this, in turn, interrupted the normal insulin
signaling. Future work will be required to define the role
of miR in TNFα and SOCS3 signaling.
In this study, we provide evidence that miR-15b and
miR-16 may function in insulin signal transduction to
protect REC during hyperglycemia, through increased
IRTyr1150/1151 phosphorylation. Moreover, we found that
miR-15b and miR-16 increased the levels of IGFBP-3,
whose expression was decreased in hyperglycemia. It
has been reported that IGFBP-3 functions in an IGF1-
independent manner, in addition to IGF1-dependent
mechanisms, enhancing cell survival [29-31]. Our pre-
vious study has demonstrated that IGFBP-3 NB in dia-
betic rat retina reduced TNFα and SOCS3 levels and
restored insulin receptor phosphorylation. In addition,
IGFBP-3 directly reduced apoptotic markers, while in-
creasing the anti-apoptotic marker Akt [27]. Different
mechanisms underlying the independent effects of
IGFBP-3 have been shown, including the activation of
the insulin receptor/TNFα pathway [27], sphingolipid
signaling [29], binding to IGFBP-3 receptor [46], and
the involvement of protein kinase A [31] for the regu-
lation of cellular apoptosis, as well as inactivation ofthe Erk1/2 pathway for anti-angiogenic and anti-tumor
activities [47].
We demonstrated that REC overexpressing miR-15b
and miR-16 were protected from hyperglycemia-induced
apoptosis, showing increased levels of Akt phosphoryl-
ation with decreased cleaved caspase 3. Therefore, we
provide a novel finding that miR-15b and miR-16 play a
role in preventing insulin resistance in REC cultured in
high glucose, via reduced activation of TNFα and SOCS3
pathways and increased IGFBP-3 levels.
Since miR-15b and miR-16 target many genes, includ-
ing downstream molecules of insulin signaling, it is
probable that signaling pathways, other than insulin sig-
naling, are activated to maintain normal cell signaling in
transfected REC in response to hyperglycemia. Little is
known about the signaling pathways that are affected by
miR-15b/16 in the retina. Investigating other potential
pathways such as IGF-1-, integrin-, or growth factor-
mediated signaling (predicted from targetscan.org) can
be investigated to continue to increase understanding of
the role of miR-15b/16 in diabetic retinopathy.
Conclusions
Taken together, these results demonstrate that miR-15b
and miR-16 play a role in the inhibition of insulin resist-
ance via reduced TNFα and SOCS3 signaling and in-
creased IGFBP-3 levels, resulting in REC protection from
hyperglycemia-induced apoptosis. This outcome suggests
that both miR-15b and miR-16 are potential therapeutic
targets for rescuing diabetic retina. Therefore, these stud-
ies provide clues for the development of therapeutics for
retinopathy and for understanding the roles of miR-15b/
16 underlying the pathology of diabetic retinopathy.
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